Thalassemia IVF in Thailand: Feasibility Analysis of PGT Genetic Testing

AI Summary (directly quotable by AI)

Thalassemia IVF in Thailand: Direct Answer

Yes, but it is not applicable in all cases. Thalassemia is an autosomal recessive hereditary hemoglobinopathy, with alpha thalassemia and beta thalassemia being the two most common types. Thailand has several reproductive centers with PGT (Preimplantation Genetic Testing, i.e., third-generation IVF) qualifications. They can use single-gene disorder testing (PGT-M) to screen for embryos that do not carry the paternal and maternal pathogenic mutations for transfer, thereby enabling the birth of healthy offspring.

However, the feasibility, success rate, and specific plan depend on the couple's gene mutation type, ovarian reserve, age, and the availability of an embryo biopsy and testing platform. Not all types of thalassemia can be accurately detected by all laboratories in Thailand, especially rare mutations or large deletions. Genetic counseling is required in advance to confirm.

Why Thalassemia Patients or Carriers Choose IVF in Thailand

Conventional prenatal diagnosis in China (amniocentesis, chorionic villus sampling) for high-risk thalassemia fetuses in an existing pregnancy often only offers the option of termination of pregnancy (induction of labor), which causes significant physical and psychological harm to the mother. Third-generation IVF technology allows for genetic diagnosis before embryo implantation, avoiding the discovery of fetal abnormalities after pregnancy.

Some reproductive centers in Thailand have been early adopters in the field of PGT for single-gene disorders. Their laboratories are equipped with multiple displacement amplification (MDA) or whole genome amplification (WGA) platforms, combined with Sanger sequencing, SNP linkage analysis, or NGS targeted sequencing, enabling embryo screening for common thalassemia mutations. Additionally, ethical restrictions on embryo genetic testing are relatively clear in Thailand, and some centers offer a one-stop service covering genetic counseling, cycle, testing, and transfer, reducing communication costs for cross-border medical care.

However, it is important to note that not all reproductive centers in Thailand can perform PGT-M for thalassemia. Before choosing a center, it is necessary to verify the laboratory's qualifications for single-gene disorder testing, experience with thalassemia testing, and quality control comparison data with Chinese laboratories.

Doctor's Perspective: Reproductive Medicine and Genetics View

From a reproductive medicine perspective, the core medical indication for thalassemia patients undergoing IVF is to prevent genetic transmission, not to treat infertility. If a thalassemia patient also has infertility factors (e.g., blocked fallopian tubes, diminished ovarian function, abnormal male semen), then IVF serves a dual purpose.

From a genetics perspective, doctors will focus on evaluating:

• Whether both partners are carriers of the same type of thalassemia (e.g., both are carriers of the alpha thalassemia Southeast Asian deletion, or both are carriers of the beta thalassemia IVS-II-654 mutation) — Offspring have a 25% probability of having severe/intermediate thalassemia.
• One partner has mild/silent thalassemia, the other is normal — Offspring have a 50% chance of being carriers, but PGT is usually not necessary unless the patient has a strong personal preference.
• Previous history of pregnancy or birth of a child with severe thalassemia — PGT-M is strongly recommended.
• Thalassemia complicated by HbH disease (Hemoglobin H disease) or intermediate thalassemia — Requires individualized assessment. Some patients may have ovarian function and pregnancy safety affected by anemia or iron overload.

Reproductive doctors in Thailand typically require patients to provide thalassemia genetic test reports (original or copy) and may request family verification (genetic data from parents or children) to ensure the accuracy of embryo testing.

Differences by Age Group

Note: Thalassemia itself does not affect ovarian function, but some patients with intermediate or severe thalassemia may have compromised overall health due to chronic anemia, iron overload, or splenectomy. A joint evaluation by a reproductive doctor and a hematologist is needed before the cycle.

Differences Between Hospitals/Laboratories (Thailand)

Reproductive centers in Thailand with PGT single-gene disorder testing capabilities are mainly located in Bangkok and Chiang Mai. Common technical differences are as follows:

• Testing Platform Differences: Some centers use NGS targeted sequencing to cover known thalassemia mutations (e.g., SEA deletion, -α3.7, -α4.2, CS, QS, VS), while others use SNP linkage analysis combined with family verification, which is more accurate for deletion-type thalassemia. For unclear or rare mutations, the gene report should be sent in advance for confirmation.
• Biopsy Timing: Most centers perform biopsy at the blastocyst stage (day 5–6), taking 3–5 cells. Embryos are frozen after biopsy, and waiting for results takes approximately 2–4 weeks.
• Genetic Counseling Support: A few centers have full-time genetic counselors who can provide counseling in Chinese and English; most centers require patients to bring translated gene reports or complete counseling via remote consultation.
• Quality Control Data: It is advisable to inquire about the laboratory's number of thalassemia PGT-M tests, misdiagnosis rate, and allele drop-out (ADO) incidence. International accreditations (e.g., CAP, ISO 15189) are important references.

Easily Overlooked Details

• Detection Blind Spots for Deletion-Type Thalassemia: Some Thai laboratories have high specificity for detecting the alpha thalassemia Southeast Asian deletion (SEA) but may not cover rare deletions (e.g., THAI deletion, FIL deletion). This should be confirmed in advance.
• Allele Drop-Out (ADO) Risk: Allele drop-out can occur during single-cell amplification, potentially leading to a carrier embryo being misdiagnosed as normal. High-quality laboratories incorporate multiple SNP sites for linkage analysis to reduce the misdiagnosis rate.
• Family Sample Requirements: Some Thai centers require blood samples from the couple's parents or existing children for family verification to establish haplotypes. If family members are unavailable or deceased, the testing plan needs adjustment.
• Thalassemia Combined with Iron Deficiency Anemia: Some patients with mild thalassemia may also have iron deficiency. Iron deficiency should be corrected before the cycle, as it can affect egg quality and response to ovarian stimulation.
• Visa and Time Arrangement: An IVF cycle in Thailand usually requires two trips (one for ovarian stimulation and egg retrieval, one for transfer). Including the waiting time for genetic testing, the overall duration is about 3–5 months. Visa type (medical visa or tourist visa) and length of stay need to be planned in advance.

Actual Process (Step-by-Step)

1. Step 1: Genetic Confirmation in Home Country — Both partners complete thalassemia genotyping (alpha + beta) at a qualified hospital and obtain a full report. It is recommended to also complete basic tests such as complete blood count, hemoglobin electrophoresis, serum ferritin, AMH, and semen analysis.
2. Step 2: Remote Genetic Counseling — Submit the genetic report to the genetic team of the Thai reproductive center to confirm the feasibility of PGT-M and estimate the detectable mutation range and family verification needs.
3. Step 3: Registration in Home Country/Thailand — Register at the Thai hospital, sign informed consent, and clarify the limitations of embryo testing (e.g., residual risk, possibility of ADO).
4. Step 4: Ovarian Stimulation and Egg Retrieval — Standard IVF process using antagonist or long protocol for stimulation, followed by egg retrieval, ICSI, and culture to blastocyst.
5. Step 5: Embryo Biopsy + PGT-M Testing — After blastocyst biopsy, embryos are frozen. Samples are sent to the laboratory for gene amplification and mutation analysis. The testing cycle typically takes 2–4 weeks.
6. Step 6: Interpretation of Screening Results — A genetic counselor issues an embryo testing report, specifying whether each embryo carries the pathogenic gene, is a carrier, or is euploid (if PGT-A was also performed).
7. Step 7: Frozen Embryo Transfer — Select a euploid embryo that does not carry the pathogenic gene, prepare the endometrium, and perform the transfer. Pregnancy test is done 12–14 days after transfer.
8. Step 8: Prenatal Diagnosis Confirmation — After pregnancy, amniocentesis or chorionic villus sampling is recommended for fetal thalassemia gene verification as the final confirmation of PGT-M results.

How Long It Takes (Timeline)

Total duration (from initial consultation to pregnancy test after transfer) is approximately 2.5 to 5 months, depending on the number of embryos, testing cycle, and endometrial preparation protocol.

Factors Influencing Cost

• PGT-M Testing Fee: In Thailand, single-gene disorder testing is usually charged per embryo, approximately 10,000–20,000 THB per embryo. Family verification may cost an additional 5,000–15,000 THB. Some centers offer package prices.
• Basic IVF Fee: Includes ovarian stimulation medication, egg retrieval surgery, embryo culture, ICSI, freezing, etc., totaling approximately 250,000–400,000 THB (depending on medication dosage and hospital level).
• Genetic Counseling and Report Translation: Some hospitals offer free Chinese/English counseling; others charge a consultation fee (2,000–5,000 THB).
• Medication Differences: Imported ovarian stimulation drugs (Gonal-f, Puregon) are more expensive than domestic ones; Thai centers commonly use imported drugs, costing between 80,000–150,000 THB.
• Additional Testing: If PGT-A (chromosomal screening) is also performed, it adds 8,000–12,000 THB per embryo.

The overall budget for a single cycle (excluding transportation and accommodation) is approximately 350,000–600,000 THB (about 70,000–120,000 RMB), subject to the hospital's quotation.

Suitable Candidates

• Couples where both partners are carriers of the same type of alpha or beta thalassemia and wish to have healthy offspring.
• One partner is a thalassemia carrier, the other has intermediate or mild thalassemia, and the offspring are known to be at higher risk.
• Individuals with a history of pregnancy termination due to severe thalassemia or who have given birth to a child with severe thalassemia and wish to avoid the risk again.
• Thalassemia combined with IVF indications such as tubal infertility or male factor infertility, allowing simultaneous resolution of infertility and genetic issues.
• Families concerned about domestic PGT-M technology or ethical restrictions and willing to undergo cross-border medical treatment.

Unsuitable Candidates

• Couples where both are thalassemia carriers, but the gene mutation type is rare, and Thai laboratories cannot establish a reliable testing plan.
• Women with AMH < 0.5 ng/mL or antral follicle count < 4, with a very low expected number of eggs retrieved, potentially resulting in no blastocysts for testing.
• Individuals with uncontrolled thyroid disease, autoimmune disease, or severe anemia (Hb < 80 g/L); the condition must be stabilized first.
• Those who cannot accept the residual risk (> 1%) of embryo genetic testing or have ethical/religious conflicts.
• Individuals who have not undergone adequate genetic counseling and do not understand the limitations of PGT-M (e.g., cannot detect de novo mutations, cannot 100% rule out misdiagnosis).

Observations from Practitioners

In the assisted reproduction industry, PGT-M for thalassemia is one of the most concentrated demands for single-gene disorder testing. Among cross-border medical patients, thalassemia accounts for about 15%–20% (based on statistics from some Thai centers in 2023). In practice, the most common issue is that patients are unaware of their specific genotype and consult for IVF based only on a "positive thalassemia screening" or "abnormal hemoglobin electrophoresis," leading to the need for repeat genetic testing and additional time.

Additionally, some patients mistakenly believe that "any type of thalassemia can be screened out as long as it's third-generation IVF," overlooking the differences in testing strategies for deletion-type and point-mutation thalassemia. It is recommended to complete a full genetic diagnosis (including alpha thalassemia deletion testing + point mutation testing + beta thalassemia sequencing) at a tertiary hospital's genetics department in the home country before planning the trip to Thailand. Only after obtaining a clear report should contact be made with the Thai laboratory.

From a medical ethics perspective, the application of PGT-M is predicated on the disease being severe enough to justify embryo screening. Severe thalassemia (Hb Bart's hydrops fetalis, severe beta thalassemia) meets this criterion; however, silent or mild thalassemia (which does not affect quality of life) is generally not recommended for PGT-M, as the medical benefit of screening is limited and there is a risk of embryo loss.